Growth Metrics

Adma Biologics (ADMA) Long-Term Debt Repayments (2016 - 2025)

Historic Long-Term Debt Repayments for Adma Biologics (ADMA) over the last 12 years, with Q3 2025 value amounting to $2.5 million.

  • Adma Biologics' Long-Term Debt Repayments fell 9166.67% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $221.1 million, marking a year-over-year increase of 1723.37%. This contributed to the annual value of $60.0 million for FY2024, which is 6216.52% down from last year.
  • According to the latest figures from Q3 2025, Adma Biologics' Long-Term Debt Repayments is $2.5 million, which was down 9166.67% from $30.0 million recorded in Q4 2024.
  • Over the past 5 years, Adma Biologics' Long-Term Debt Repayments peaked at $158.6 million during Q4 2023, and registered a low of $2.5 million during Q3 2025.
  • In the last 4 years, Adma Biologics' Long-Term Debt Repayments had a median value of $30.0 million in 2024 and averaged $64.2 million.
  • In the last 5 years, Adma Biologics' Long-Term Debt Repayments tumbled by 8108.26% in 2024 and then plummeted by 9166.67% in 2025.
  • Quarter analysis of 4 years shows Adma Biologics' Long-Term Debt Repayments stood at $100.0 million in 2022, then skyrocketed by 58.58% to $158.6 million in 2023, then crashed by 81.08% to $30.0 million in 2024, then tumbled by 91.67% to $2.5 million in 2025.
  • Its Long-Term Debt Repayments was $2.5 million in Q3 2025, compared to $30.0 million in Q4 2024 and $30.0 million in Q3 2024.